RESEARCH ARTICLE

Role of metastasis-associated protein 1 in prognosis of patients with digestive tract cancers: A meta-analysis

Guo-dong Cao1, Bo Chen2*, Mao-ming Xiong2*

1 Anhui Medical University, Hefei, Anhui, China, 2 Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

* chenbo831116@163.com (BC); ayfyxmm@163.com (MMX)

Abstract

Objectives
Metastasis-associated protein 1 (MTA1) is a transcriptional regulator and significantly associated with prognosis of patients with cancer. However, its role as a potential prognostic marker in digestive tract cancer (DTC) is controversial. In this study, a meta-analysis was conducted to evaluate the MTA1 expression as a predictor of clinicopathology and survival of patients with DTC.

Methods
We searched PubMed, Ovid, Web of Science and Cochrane databases using multiple search strategies for eligible studies. STATA 11.0 software was used to pool the data and analyze the association, odds ratios (ORs) and 95% confidence intervals (CIs) were used to measure the strength of the association. Furthermore, the Newcastle-Ottawa scale was used to evaluate the quality of eligible studies.

Results
MTA1 overexpression was strongly associated with depth of invasion (OR = 1.88, 95%CI: 1.05–3.37, \( P = 0.03 \)), lymph node metastasis (OR = 2.30, 95%CI: 1.76–3.01, \( P<0.001 \)), vascular invasion (OR = 2.02, 95%CI: 1.40–2.91, \( P<0.001 \)) and TNM stage (OR = 2.78, 95%CI: 1.63–4.74, \( P<0.001 \)), and was related to 1- (RR = 1.84, 95%CI: 1.18–2.89, \( P = 0.008 \)), 3- (RR = 1.90, 95%CI: 1.32–2.30, \( P<0.001 \)) and 5-year (RR = 2.17, 95%CI: 1.41–3.32, \( P<0.001 \)) DFS. In subgroup analyses based on study quality and tumor type, MTA1 overexpression was obviously related to clinical parameters, such as lymph node metastasis and TNM stage, and was also associated with prognosis of patients with gastrointestinal or esophageal cancer.
Conclusions

MTA1 expression is strongly correlated with metastasis-related variables, and represents a promising prognostic factor in DTC.

Introduction

Digestive tract cancers (DTCs) are a heterogeneous group of gastrointestinal (GI) cancers as well as hepatobiliary and pancreatic tumors. DTCs are important causes of cancer-related deaths worldwide [1–2]. Data from the Global Cancer Statistics, 2012 [1] indicate that colorectal cancer (CRC), gastric cancer (GC), and esophageal cancer (EC) rank fourth, sixth, and tenth among all DTCs.

DTC increases the risk of lymph node metastasis and distant metastasis. Lymph node status and distant metastasis are included in tumor staging, which is the most useful indicator in predicting outcomes. However, adequate evidence reminds us of the inability of conventional staging criteria to differentiate prognostic features of DTC. Metastasis is a multi-step process encompassing dissemination of primary cancer cells and subsequent colonization at distant sites [3], and is the overwhelming cause of morbidity and mortality in patients with cancer. Therefore, elucidation of the mechanism and development of new strategies to prevent metastasis are essential to combating cancers.

Several factors are associated with the prognosis of cancer and regulation of metastasis. Metastasis-associated proteins (MTAs), especially MTA1, play prominent roles. MTA1 belongs to MTA family (consisting of MTA1, MTA2 and MTA3) that is associated with the nucleosome remodeling and histone deacetylation (NuRD) complex, which regulates transcription via histone deacetylation and chromatin remodeling [4]. MTA1 was first reported in metastatic rat breast adenocarcinoma cell lines, where it was highly expressed compared with poorly metastatic cell lines. It plays a key role as a tumor invasion and metastasis-related gene [5]. Toh et al. [6] found that higher mRNA levels of MTA1 were closely related to depth of invasion and lymph node metastasis and a tendency toward a higher rate of lymphatic involvement. Song et al. [7] found that overexpression of MTA1 protein is an independent prognostic risk factor, and is associated with shorter disease-free survival and lower 5-year survival rate.

To the best of our knowledge, only one meta-analysis reviewed the prognostic significance of MTA1 in solid tumors. The prognostic value of MTA1 in DTC is inconclusive and controversial. Therefore, we conducted a meta-analysis to investigate the role of MTA1 expression in the prognosis and survival of patients with DTC.

Methods

Search strategy

Two investigators independently searched PubMed, Ovid, Web of Science, Cochrane databases for studies published until Jul 2016. The search terms used were: (“MTA1” OR “Metastasis-associated protein 1”) AND (“esophagus” OR “esophageal” OR “oesophagus” OR “gullet” OR “esophago-cardiac” OR “colon” OR “colorectal” OR “rectal” OR “anal” OR “pancreas” OR “pancreatic” OR “liver” OR “hepatic” OR “biliary duct” OR “bile duct” OR “gastric” OR “stomach” OR “cardia” OR “digestive tract”) AND (“carcinoma” OR “cancer” OR “tumour” OR “tumour” OR “tumor” OR “malignancy”). The full texts of the studies were retrieved to determine their eligibility for inclusion in the meta-analysis.
Inclusion and exclusion criteria

The inclusion criteria were: (1) DTC diagnosis; (2) studies using immunohistochemistry (IHC); (3) correlation between MTA1 and DTC; and (4) studies published in English language. The exclusion criteria were: (1) redundant data; (2) reviews; (3) case reports; (4) studies without IHC analysis; and (5) inaccurate data.

Data extraction and assessment

All the pertinent data were extracted independently from each eligible study by two investigators (Guo-dong Cao, Bo Chen). Any disagreement was resolved through discussion until a consensus was reached. The following data were extracted: first author’s name, year of publication, total number of patients, clinicopathological parameters, and survival time. Two researchers independently evaluated the quality of eligible studies using the Newcastle-Ottawa scale [8].

Statistical analysis

All the statistical analyses were performed using the STATA software (version 11.0, StataCorp LP, College Station, TX, USA). The crude odds ratios (OR) and 95% confidence intervals (CI) were used to estimate the strength of association between MTA1 and clinicopathological parameters. Risk ratios (RR) and 95% CIs were used to estimate the association of MTA1 status with the overall survival (OS) and disease-free survival (DFS). $I^2$ value, which indicated the percentage of total variation across studies, was used to assess statistical heterogeneity. Random-effects models ($I^2 > 50\%$ or $P < 0.10$) were used if significant heterogeneity was detected. Otherwise, fixed-effects models were used. Begg’s rank correlation and Egger’s weighted regression were used to determine potential publication bias. $P$ value less than 0.05 indicates statistically significant publication bias.

Results

Study characteristics

The search strategy identified 76 studies potentially eligible for the relationship between MTA1 protein overexpression and DTC. After reading the titles, 23 studies were probably eligible. After browsing the abstracts and full text, 5 studies on MTA1 and EC [7, 9–12], 3 studies on MTA and GC [13–15], 2 studies on MTA1 and CRC [16–17], 2 studies on MTA1 and liver cancer [18–19] and one study on MTA1 and pancreatic cancer [20] met the inclusion criteria, respectively (Fig 1). Full details of all the included studies are summarized in Table 1 and Table 2. The MTA1 expression in 1,997 DTC patients was studied, and the number of patients ranged from 39 to 506 patients in 13 different included studies. These studies used immunohistochemistry (IHC) to analyze the MTA1 status of DTC samples, and results were performed in their studies. Furthermore, the overall MTA1 positive expression rate in DTC patients was 35.8% (714/1997). Over-expression rate was 43.7% (289/662) in EC, 47.3% (157/332) in GC, 40.6% (63/155) in CRC, 33.3% (13/39) in pancreatic cancer and 23.7% (192/809) in liver cancer, respectively.

Relationship between MTA1 expression and clinicopathological parameters

MTA1-positive expression was significantly associated with several types of metastasis-related clinical parameters. As shown in Table 3, MTA1 over-expression was strongly correlated with
depth of invasion (OR = 1.88, 95%CI: 1.05–3.37, \( P = 0.03 \), Fig 2A), lymph node metastasis (OR = 2.30, 95%CI: 1.76–3.01, \( P < 0.001 \), Fig 2B), vascular invasion (OR = 2.02, 95%CI: 1.40–2.91, \( P < 0.001 \), Fig 3A) and TNM stage (OR = 2.78, 95%CI: 1.63–4.74, \( P < 0.001 \), Fig 3B).

MTA1-positive expression increased the risk for stomach wall invasion, lymph node-positive metastasis and vascular invasion, leading to a later TNM stage. Other clinicopathological variables such as gender, age, tumor size, differentiation or distant metastasis were not correlated with MTA1 expression.

**Correlation of MTA1 overexpression with OS and DFS**

Survival time was extracted from Kaplan–Meier survival curves analyzed by the Enguage Digitizer software. In the present study, as shown in Table 4, MTA1 expression was not only clearly linked to OS, but also showed significant association with DFS. DTC patients with
Table 1. Clinicopathological parameters and quality scores of studies comparing MTA1 positive digestive tract cancer with MTA1 negative digestive tract cancer.

| Study Year | Tumor type | Number of patient | Sex | Age | Tumor size | Differentiation | Depth of invasion | LN metastasis | Distant metastasis | Tumor stage | Vascular invasion | Quality score |
|------------|------------|-------------------|-----|-----|------------|----------------|------------------|--------------|------------------|-------------|-----------------|----------------|
| Toh 2004   | Esophageal  | 70 (30 vs. 40)    | Male | 24/6 | <50 | No.6 | No.8 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Yang 2016  | Esophageal  | 197 (83 vs. 114)  | Male | 24/6 | >50 | No.5 | No.5 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Li 2012    | Esophageal  | 131 (57 vs. 74)   | Male | 24/6 | <50 | No.6 | No.8 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Li 2009    | Esophageal  | 90 (40 vs. 50)    | Male | 24/6 | >50 | No.5 | No.5 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Song 2013  | Esophageal  | 117 (56 vs. 61)   | Male | 24/6 | <50 | No.6 | No.8 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Deng 2013  | Gastric    | 111 (40 vs. 71)   | Male | 24/6 | >50 | No.5 | No.5 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Yao 2015   | Gastric    | 61 (47 vs. 14)    | Male | 24/6 | <50 | No.6 | No.8 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Meng 2015  | Gastric    | 160 (70 vs. 90)   | Male | 24/6 | >50 | No.5 | No.5 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Higashijima 2011 | Colorectal | 74 (39 vs. 36) | Male | 24/6 | <50 | No.6 | No.8 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Du 2011    | Colorectal | 81 (52 vs. 29)    | Male | 24/6 | >50 | No.5 | No.5 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Miyake 2007 | Pancreatic | 39 (12 vs. 27)    | Male | 24/6 | <50 | No.6 | No.8 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Jin 2012   | Hepatic    | 303 (104 vs. 199) | Male | 24/6 | >50 | No.5 | No.5 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |
| Ryu 2008   | Hepatic    | 506 (88 vs. 418)  | Male | 24/6 | <50 | No.6 | No.8 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | Yes/10 | 13/17 | 28/12 | 15/15 | 11/29 |

LN: lymph node; NA: not available
TNM stages are based on tumor-node-metastasis classification advocated by International Union against Cancer
Quality score: use the Newcastle-Ottawa scale (stars)

https://doi.org/10.1371/journal.pone.0176431.t001
Table 2. IHC antibodies and assessment methods of MTA1 expression in the eligible studies.

| Study | Year | Tumor Type | Antibody | Antibody Concentration | The Positive-cell Scoring | Staining Intensity | IHC Assessment Method |
|-------|------|------------|----------|------------------------|---------------------------|------------------|----------------------|
| Toh   | 2004 | Esophageal | NA       | NA                     | NA                        | Score: no staining (0); slight staining (+); moderate staining (++); intense staining (+++). | Scores were compared between the carcinoma tissues and the normal squamous epithelium contained in the same section. In all cases, the normal epithelial cells were scored (+), and the scores (+) and (++) in the carcinoma tissues were defined as overexpression of MTA1 protein |
| Yang  | 2016 | Esophageal | sc-9446, Santa Cruz Biochemistry | 1/100 | Positive: <5%, 0 points; 5–25%, 1 point; 26–50%, 2 points; 51–75%, 3 points; and >75%, 4 points. | Staining intensity: Minimal staining similar to the background, 0 points; lightly stained, more than the background and pale yellow, 1 point; moderately stained, markedly more than the background and a brown-yellow, 2 points; and clearly stained a dark brown-yellow or tan, 3 points. | Total score: number of positive cells x staining intensity. Total score >5 indicated a positive result, and <5 indicated a negative result. |
| Li    | 2012 | Esophageal | sc-9446, Santa Cruz Biotechnology | 1/100 | Positive: 0, 0–5%; 1, 6–25%; 2, 26–50%; 3, 51–75%; 4, >76% | Staining intensity: 0, negative; 1, weak; 2, moderate; 3, strong | The final staining score was the sum of the scores of staining intensity and percentage of positive cells, ranging from 0 to 7. |
| Li    | 2009 | Esophageal | sc-9446, Santa Cruz Biotechnology | 1/100 | NA | Staining intensity and proportion of the stained tumor nuclei as follows: score 0, no staining; (+), slight staining; (++), moderate staining; (+++), intense staining. | For all cases, the normal epithelial cells that were scored (+), and the cancer tissues that were scored (+++) and (++++) were defined as overexpression of MTA1 protein |
| Song  | 2013 | Esophageal | sc-9446, Santa Cruz Biochemistry | 1/100 | Positive: 0, 0–5%; 1, 6–25%; 2, 26–50%; 3, 51–75%; 4, >76% | Staining intensity: 0, negative staining; 1, weak staining; 2, moderate staining; 3, intense staining | The final staining score was the sum of the scores of staining intensity and percentage of positive cells: (-), 0 to 1; (+), 2 to 3; (++), 4 to 5; (+++), 6 to 7. |
| Deng  | 2013 | Gastric    | sc-9446, Santa Cruz Biochemistry | 1/100 | NA | The results were reported as follows: 0, no staining; +, slight staining; ++, moderate staining; ++++, intense staining. | The cancer tissues scored as ++ and +++ were defined as exhibiting overexpression of MTA1 protein |
| Yao   | 2015 | Gastric    | Santa Cruz Biochemistry | 1/500 | Positive: 0%, negative, 5%, weak positive; 5%–25%, intermediate; 25%–50%, moderate; 50%–100%, strong | NA | The distribution of tumor cells in all experimental groups was determined as follows: 0%–5% lower expression and 5%–100% is higher expression. |
| Meng  | 2015 | Gastric    | # 5647, Cell Signaling | 1/100 | <25%, 1; 25–50%, 2; >50%–75%, 3; >75%, 4 scores | Staining intensity: negative, 0; weak, 1; moderate, 2; or strong, 3 scores | A staining index (values 0–12), >6 indicated a positive result. |

(Continued)
MTA1-positive expression manifest shorter OS. MTA1 expression was significantly correlated with 1- (RR = 1.84, 95%CI: 1.18–2.89, \( P = 0.008 \)), 3- (RR = 1.74, 95%CI: 1.32–2.30, \( P < 0.001 \)) and 5- (RR = 1.64, 95%CI: 1.18–2.27, \( P = 0.003 \), Fig 4A) year OS. Further, MTA1 expression was linked to 1- (RR = 4.16, 95%CI: 1.35–12.81, \( P = 0.01 \)), 3- (RR = 1.90, 95%CI: 1.02–3.53, \( P = 0.04 \)) and 5- (RR = 2.17, 95%CI: 1.41–3.32, \( P < 0.001 \), Fig 4B) year DFS.

**Subgroup analyses**

In order to further investigate the relationship between MTA1 and prognosis of DTC, all the eligible studies were divided into several subgroups according to the quality of each study and tumor type (Table 5). High-quality studies were divided into high quality studies subgroup. And according to tumor type, we investigated MTA1 expression in patients with gastrointestinal cancers (GI cancers) or EC.

In the subgroup containing high-quality studies, similar results of MTA1 expression showed a higher risk of lymph node metastasis (OR = 2.62, 95%CI: 1.89–3.63, \( P < 0.001 \), Fig 5A), advanced TNM stage of DTC (OR = 3.81, 95%CI: 2.38–6.12, \( P < 0.001 \)) and a greater possibility of vascular invasion (OR = 1.95, 95%CI: 1.31–2.90, \( P = 0.001 \)). However, MTA1 expression was not related to any other clinical parameters. All studies were of high quality, and the results were reliable.

MTA1 is also associated with metastasis-related clinical variables and prognosis in patients with GI cancers (including EC, GC and CRC). MTA1 is inextricably associated with depth of invasion (OR = 1.88, 95%CI: 1.05–3.37, \( P = 0.03 \)), lymph node metastasis (OR = 2.33, 95%CI: 1.77–3.06, \( P < 0.001 \), Fig 5B), TNM stage (OR = 2.78, 95%CI: 1.63–4.74, \( P < 0.001 \)) and vascular...
invasion (OR = 2.22, 95%CI: 1.38–3.56, P < 0.001) of GI cancers. MTA1 was significantly related to EC in GI cancers. Elevated expression of MTA1 was always associated with depth of invasion (OR = 2.60, 95%CI: 1.88–3.61, P < 0.001), lymph node metastasis (OR = 2.17, 95%CI: 1.55–3.04, P < 0.001, Fig 5C), and TNM stage (OR = 2.54, 95%CI: 1.66–3.88, P < 0.001), consistent with previous meta-analysis. Moreover, MTA1 high expression is relatively associated with the clinico-pathological variables of GC and CRC patients (Table 5).

In all the subgroups (Table 6), MTA1-positive expression was strongly correlated with 1-, 3- and 5-year OS. Among the high-quality studies, MTA1 expression was associated with 1- (RR = 1.96, 95%CI: 1.11–3.44, P = 0.02), 3- (RR = 1.73, 95%CI: 1.20–2.49, P = 0.003) and 5- (RR = 1.49, 95%CI: 1.28–1.72, P < 0.001, Fig 6A) year OS. Further, GI patients with increased MTA1 expression manifest shorter 1- (RR = 1.66, 95%CI: 1.21–2.26, P = 0.001), 3- (RR = 1.87, 95%CI: 1.27–2.26, P = 0.002) and 5- (RR = 1.89, 95%CI: 1.41–2.53, P < 0.001, Fig 6B) year OS. Similar to GI cancers, MTA1-positive expression increased the risk of death postoperatively. MTA1 was linked to 1- (RR = 1.39, 95%CI: 1.01–1.91, P = 0.04), 3- (RR = 1.75, 95%CI: 1.06–2.88, P = 0.03) and 5- (RR = 1.82, 95%CI: 1.24–2.67, P = 0.002, Fig 6C) in EC patients.

### Sensitivity analysis and publication bias

In order to test the robustness of RR estimates in OS, sensitivity analysis was conducted by individually excluding studies and analyzing the effects of the remaining studies. Sensitivity analysis (S1 Fig) indicated that the RR estimates were relatively reliable and credible as no point estimate of the omitted study fell outside the 95% CI.

Begg’s rank correlation and Egger’s weighted regression methods were used to statistically assess publication bias. As shown in Fig 7A and 7B, neither Begg’s (P = 0.35) nor Egger’s (P = 0.13) test provided a clear evidence of publication bias. No publication bias was detected in the current study. The results reported in this article are credible.

### Discussion

Depth of invasion (T), lymph node metastasis (N), and the presence of distant metastasis (M)—TNM stage was considered as the most important prognostic factors for DTC, such as GC [21]. However, large clinical case studies suggest that patients at similar pathological

---

### Table 3. Meta-analysis of a putative association between clinicopathological parameters and MTA1 expression in digestive tract cancer.

| Parameters                           | Number of studies | Number of patients | Heterogeneity | Model   | OR(95% CI)          | P value |
|--------------------------------------|-------------------|--------------------|---------------|---------|---------------------|---------|
| Sex (male/female)                    | 12                | 1491               | 16            | FE      | 0.84(0.67,1.07)     | 0.16    |
| Age (<60/>60)                        | 2                 | 278                | 0             | FE      | 0.96(0.59,1.56)     | 0.87    |
| Tumor size (<5cm/>5cm)               | 7                 | 1050               | 74            | RE      | 0.58(0.34,1.01)     | 0.06    |
| Differentiation (well/poor)          | 9                 | 968                | 44            | RE      | 0.66(0.28,1.54)     | 0.34    |
| Depth of invasion (T1+T2/T3+T4)      | 9                 | 1118               | 79            | RE      | 1.88(1.05,3.37)     | 0.03    |
| LN metastasis (positive/negative)    | 9                 | 986                | 0             | RE      | 2.30(1.76,3.01)     | <0.001  |
| Metastasis (positive/negative)       | 2                 | 113                | 0             | FE      | 1.32(0.56,3.10)     | 0.52    |
| Tumor stage (early/advanced)         | 6                 | 591                | 52            | RE      | 2.78(1.63,4.74)     | <0.001  |
| Vascular invasion (positive/negative)| 4                 | 607                | 0             | FE      | 2.02(1.40,2.91)     | <0.001  |

LN metastasis: lymph node metastasis
TNM stages are based on tumor-node-metastasis classification advocated by International Union against Cancer
OR: odds ratio; CI: confidence interval; FE: fixed-effect model; RE: random-effect model

https://doi.org/10.1371/journal.pone.0176431.t003
stages of DTC may differ substantially in survival after complete surgical resection. Therefore, the current staging system is inadequate for accurate prognosis. Prognosis of DTC is always predicted by TNM staging clinically. However, TNM staging lacks sensitivity. In our opinion, EC and liver cancer always show a high risk of tumor recurrence and metastasis, despite complete resection or targeted therapy. Several deaths among DTC patients are still attributed to local recurrence and/or distant metastasis. A new prognostic marker is needed to identify patients with poor survival time or indicate those with a higher risk of tumor metastasis.

Members of the MTA family play a vital role in both physiological and pathophysiological processes, especially in cancer development and distant metastasis. MTA family members regulate metastasis. MTAs including MTA1, MTA2, and MTA3 are expressed in different isoforms (MTA1, MTA1s, MTA-ZG29p, MTA2, MTA3, and MTA3L) [22–23]. MTA1 is a founding member of this family and was first identified as a metastasis-associated tumor gene differentially
expressed in rat metastatic tumors [24]. MTA1 overexpression has been identified in many cancers. However, the molecular functions of MTA1 were unclear until it was identified as an integral component of the NuRD complex [25]. Luo et al. [26] conducted a meta-analysis to further investigate the role of MTA1 in solid tumors, and confirmed that MTA1 expression was significantly associated with prognosis of solid cancers. Currently, the clinical and prognostic value of MTA1 in DTC is unknown. Ning et al. [27] reviewed the expression and clinical significance of MTA family, and concluded that MTA1 expression was correlated with invasion and lymph node metastasis in GI cancer. However, the prognostic value of MTA1 expression in DTC is unclear and controversial. Several studies found that MTA1-positive expression was not correlated with OS in patients with esophageal squamous cell carcinoma and breast cancer [10, 28].

In our study, we investigated the overexpression of MTA1 and clinicopathological parameters in DTC. The results demonstrate that MTA1-positive expression increased the risk of stomach wall invasion (OR = 1.88, 95%CI: 1.05–3.37, \( P = 0.03 \)), lymph node-positive metastasis (OR = 2.30, 95%CI: 1.76–3.01, \( P<0.001 \)) and vascular invasion (OR = 2.02, 95%CI: 1.40–

**Table 4. Meta-analysis of a putative association between OS/DFS and MTA1 expression in digestive tract cancer.**

| OS/DFS     | Number of studies | Number of patients | Heterogeneity | Model  | RR(95%CI)          | \( P \) value |
|------------|-------------------|--------------------|---------------|--------|--------------------|---------------|
| 1-year OS  | 11                | 1722               | 57            | 0.009  | RE                 | 1.84(1.18,2.89) | \( P = 0.008 \) |
| 3-year OS  | 11                | 1722               | 77            | 0      | RE                 | 1.74(1.32,2.30) | \( <0.001 \)  |
| 5-year OS  | 8                 | 1161               | 88            | 0      | RE                 | 1.64(1.18,2.27) | \( 0.003 \)   |
| 1-year DFS | 3                 | 224                | 16            | 0.31   | RE                 | 4.16(1.35,12.81)| \( 0.013 \)   |
| 3-year DFS | 3                 | 224                | 56            | 0.10   | RE                 | 1.90(1.02,3.53) | \( 0.044 \)   |
| 5-year DFS | 2                 | 163                | 0             | 0.45   | FE                 | 2.17(1.41,3.32) | \( <0.001 \)  |

OS: overall survival; RR: risk ratio; CI: confidence interval; FE: fixed-effect model; RE: random-effect model

https://doi.org/10.1371/journal.pone.0176431.t004

![Fig 4. Forrest plot of the risk ratio for the association of MTA1 and 5-year OS/DFS in DTC patients.](https://doi.org/10.1371/journal.pone.0176431.g004)
2.91, \( P < 0.001 \)), leading to later TNM stages (OR = 2.78, 95%CI: 1.63–4.74, \( P < 0.001 \)). Furthermore, MTA1 expression was not only linked to OS, but also showed significant association with DFS. DTC patients with MTA1-positive expression always manifested shorter OS and DFS. Similar conclusions were obtained in the three different subgroups. MTA1 expression

Table 5. Subgroup analysis: Meta-analysis of the association between clinicopathological parameters and MTA1 expression.

| Subgroup type           | Parameters                      | Number of studies | Number of patients | Heterogeneity Model | OR(95%CI)       | \( P \) value |
|-------------------------|---------------------------------|-------------------|--------------------|---------------------|-----------------|--------------|
|                         |                                 | \( \bar{I}^{2} (%) \) | \( P \) value      |                     |                 |              |
| High quality studies    | Sex (male/female)               | 8                 | 1093               |                     | 0.77(0.59,1.02) | 0.72         |
|                         | Age (<60/>60)                   | 2                 | 278                |                     | 0.69(0.59,1.56) | 0.87         |
|                         | Tumor size (<5cm/>5cm)          | 5                 | 765                |                     | 0.75(0.47,1.22) | 0.25         |
|                         | Differentiation (well/poor)     | 6                 | 681                |                     | 1.06(0.63,1.78) | 0.84         |
|                         | Depth of invasion (T1+T2/T3+T4) | 6                 | 759                |                     | 1.83(0.77,4.33) | 0.17         |
|                         | LN metastasis (positive/negative) | 6          | 700                |                     | 2.62(1.89,3.63) | \(<0.001\)   |
|                         | Tumor stage (early/advanced)    | 4                 | 343                |                     | 3.81(2.38,6.12) | \(<0.001\)   |
|                         | Vascular invasion (positive/negative) | 3          | 533                |                     | 1.95(1.31,2.90) | 0.001        |
| Gastrointestinal cancers| Sex (male/female)               | 10                | 1149               |                     | 0.96(0.73,1.25) | 0.75         |
|                         | Age (<60/>60)                   | 2                 | 278                |                     | 0.69(0.59,1.56) | 0.87         |
|                         | Tumor size (<5cm/>5cm)          | 6                 | 747                |                     | 0.49(0.28,0.87) | 0.01         |
|                         | Differentiation (well/poor)     | 8                 | 929                |                     | 1.02(0.75,1.39) | 0.88         |
|                         | Depth of invasion (T1+T2/T3+T4) | 9                 | 1118               |                     | 1.88(1.05,3.37) | 0.03         |
|                         | LN metastasis (positive/negative) | 8          | 948                |                     | 2.33(1.77,3.06) | \(<0.001\)   |
|                         | Metastasis (positive/negative)  | 1                 | 74                 |                     | 1.30(0.50,3.37) | 0.58         |
|                         | Tumor stage (early/advanced)    | 6                 | 591                |                     | 2.78(1.63,4.74) | \(<0.001\)   |
|                         | Vascular invasion (positive/negative) | 3          | 304                |                     | 2.22(1.38,3.56) | 0.001        |
| Esophageal cancer       | Sex (male/female)               | 5                 | 662                |                     | 0.95(0.67,1.36) | 0.80         |
|                         | Age (<60/>60)                   | 1                 | 197                |                     | 0.91(0.51,1.60) | 0.73         |
|                         | Tumor size (<5cm/>5cm)          | 3                 | 395                |                     | 0.66(0.43,1.00) | 0.05         |
|                         | Differentiation (well/poor)     | 5                 | 662                |                     | 0.82(0.57,1.18) | 0.29         |
|                         | Depth of invasion (T1+T2/T3+T4) | 5                 | 662                |                     | 2.60(1.88,3.61) | \(<0.001\)   |
|                         | LN metastasis (positive/negative) | 4          | 572                |                     | 2.17(1.55,3.04) | \(<0.001\)   |
|                         | Tumor stage (early/advanced)    | 3                 | 375                |                     | 2.54(1.66,3.88) | \(<0.001\)   |
|                         | Vascular invasion (positive/negative) | 1          | 70                 |                     | 2.64(0.97,7.14) | 0.06         |
| Gastric cancer          | Sex (male/female)               | 3                 | 332                |                     | 0.68(0.41,1.12) | 0.13         |
|                         | Tumor size (<5cm/>5cm)          | 2                 | 271                |                     | 0.29(0.03,0.04) | 0.13         |
|                         | Differentiation (well/poor)     | 1                 | 111                |                     | 2.08(0.95,4.57) | 0.07         |
|                         | Depth of invasion (T1+T2/T3+T4) | 2                 | 271                |                     | 2.01(1.14,3.54) | 0.02         |
|                         | LN metastasis (positive/negative) | 2          | 221                |                     | 3.35(1.72,6.51) | \(<0.001\)   |
|                         | Tumor stage (early/advanced)    | 1                 | 61                 |                     | 14.29(3.49,58.54) | \(<0.001\) | 0.045 |
|                         | Vascular invasion (positive/negative) | 1          | 160                |                     | 1.96(1.02,3.77) | 0.045        |
| Colorectal cancer       | Sex (male/female)               | 2                 | 155                |                     | 1.80(0.91,3.54) | 0.09         |
|                         | Age (<60/>60)                   | 1                 | 81                 |                     | 1.13(0.44,2.92) | 0.81         |
|                         | Tumor size (<5cm/>5cm)          | 1                 | 81                 |                     | 0.37(0.14,0.98) | 0.045        |
|                         | Differentiation (well/poor)     | 2                 | 155                |                     | 1.58(0.65,3.86) | 0.32         |
|                         | Depth of invasion (T1+T2/T3+T4) | 2                 | 155                |                     | 0.66(0.05,8.21) | 0.74         |
|                         | LN metastasis (positive/negative) | 2          | 155                |                     | 2.11(1.08,4.13) | 0.03         |
|                         | Metastasis (positive/negative)  | 1                 | 74                 |                     | 1.30(0.50,3.37) | 0.58         |
|                         | Tumor stage (early/advanced)    | 1                 | 155                |                     | 1.81(0.91,3.58) | 0.09         |
|                         | Vascular invasion (positive/negative) | 1          | 74                 |                     | 2.47(0.96,6.34) | 0.06         |

LN metastasis: lymph node metastasis; OR: odds ratio; CI: confidence interval; FE: fixed-effect model; RE: random-effect model

TNM stages are based on tumor-node-metastasis classification advocated by International Union against Cancer

https://doi.org/10.1371/journal.pone.0176431.t005
was tightly associated with clinicopathological parameters and 1-, 3-, 5-year OS in GI cancer and EC.

From a clinical perspective, MTA1 over-expression was strongly and independently correlated with depth of invasion, lymph node metastasis, vascular invasion and TNM stage. Tumor tissues expressing MTA1 show deeper invasion into the lymphatic network under the mucosa. Vascular invasion leads to advanced tumor stages, and shortens the OS of patients with DTC. Previous studies suggested that the MTA1 gene acted as a transcriptional regulator, in conjunction with other components of NURD to mediate transcriptional repression and the association of repressor molecules with chromatin [23,29–30]. For example, MTA1 protein physically interacts with HDAC1 [31]. The two proteins are the key components of NuRD complex, which contains histone deacetylase. Histone deacetylation alters chromatin structure and transcriptional control. Toh et al. [9] observed that MTA1 expression in ESCC was associated with the activity of H4 histone deacetylase. Tumor suppressor genes including p53, p21 and Bcl-2 are regulated by histone acetylation [32–33].

Table 6. Subgroup analysis: Meta-analysis of the association between OS and MTA1 expression.

| Subgroup type              | OS         | Number of studies | Number of patients | Heterogeneity | Model | RR(95% CI)       | P value |
|----------------------------|------------|-------------------|--------------------|---------------|-------|------------------|---------|
| High quality studies       | 1-year OS  | 7                 | 1324               | 65            | 0.01  | 1.96(1.11,3.44)  | 0.02    |
|                            | 3-year OS  | 7                 | 1324               | 81            | 0     | 1.73(1.20,2.49)  | 0.003   |
|                            | 5-year OS  | 4                 | 763                | 26            | 0.26  | 1.49(1.28,1.72)  | <0.001  |
| Gastrointestinal cancers   | 1-year OS  | 8                 | 874                | 48            | 0.06  | 1.66(1.21,2.26)  | 0.001   |
|                            | 3-year OS  | 8                 | 874                | 80            | 0     | 1.87(1.27,2.75)  | 0.002   |
|                            | 5-year OS  | 6                 | 616                | 68            | 0.01  | 1.89(1.41,2.53)  | <0.001  |
| Esophageal cancer          | 1-year OS  | 5                 | 689                | 48            | 0.10  | 1.39(1.01,1.91)  | 0.04    |
|                            | 3-year OS  | 5                 | 689                | 85            | 0     | 1.75(1.06,2.88)  | 0.03    |
|                            | 5-year OS  | 4                 | 431                | 78            | 0.004 | 1.82(1.24,2.67)  | 0.002   |
| Gastric cancer             | 1-year OS  | 2                 | 172                | 0             | 0.85  | 7.03(1.32,34.47) | 0.02    |
|                            | 3-year OS  | 2                 | 172                | 79            | 0.03  | 2.21(0.80,6.10)  | 0.13    |
|                            | 5-year OS  | 1                 | 111                | –             | –     | 2.40(1.47,3.93)  | <0.001  |
| Colorectal cancer          | 1-year OS  | 1                 | 74                 | –             | –     | 2.37(0.49,11.44) | 0.28    |
|                            | 3-year OS  | 1                 | 74                 | –             | –     | 2.17(1.01,4.64)  | 0.047   |
|                            | 5-year OS  | 1                 | 74                 | –             | –     | 1.80(0.97,3.33)  | 0.06    |

OS: overall survival; RR: risk ratio; CI: confidence interval; FE: fixed-effect model; RE: random-effect model

https://doi.org/10.1371/journal.pone.0176431.t006
The limitations of this meta-analysis are as follows: (1) A few eligible non-English publications were excluded; (2) IHC assessments of MTA1 were still discordant; and (3) The number of articles was inadequate. Nonetheless, the meta-analysis has several advantages: (1) This study is the first of its kind to investigate the association between MTA1 overexpression and clinicopathological parameters in DTC; (2) The study successfully evaluated the association of MTA1 expression with the OS/DFS of DTC patients.

This work was supported by grants from the National Natural Science Foundation of China (NO: 81602425) and the Natural Science Foundation of Anhui Province (NO: 1508085QH152,1608085MH163). The funders had no role in study design, data collection and analysis, manuscript preparation, or submission for publication.

In conclusion, MTA1 expression is significantly associated with clinicopathological parameters, DFS and OS in DTC patients. It may play an independent role in predicting aggressive tumor behavior and poor prognosis. The results of the meta-analysis suggest that MTA1 is a potential target for anticancer therapy. Further investigations are needed to identify the mechanisms underlying the role of MTA1.

![Fig 6. Forrest plot of the risk ratio for the association of MTA1 and OS in DTC patients: Association between MTA1 overexpression and 5-year (6a) OS in high-quality studies subgroup. Association between MTA1 overexpression and 5-year (6b) OS in gastrointestinal cancer subgroup. Association between MTA1 overexpression and 5-year (6c) OS in esophageal cancer subgroup](https://doi.org/10.1371/journal.pone.0176431.g006)

![Fig 7. Begg's funnel plot (7a) (P = 0.35) and Egger’s funnel plot (7b) (P = 0.13) for possible publication bias test of this study. There was no publication bias and the results are credible](https://doi.org/10.1371/journal.pone.0176431.g007)
Supporting information
S1 Checklist. The checklist of this meta-analysis.
(DOC)
S1 Fig. Sensitivity analysis: It indicated that eligible articles were relatively reliable and credible.
(TIF)

Author Contributions
Conceptualization: GDC BC.
Data curation: GDC.
Formal analysis: GDC BC.
Funding acquisition: BC MMX.
Investigation: GDC BC.
Methodology: GDC BC.
Project administration: MMX.
Resources: GDC BC.
Software: GDC BC.
Supervision: MMX.
Validation: MMX.
Visualization: BC.
Writing – original draft: GDC.
Writing – review & editing: BC MMX.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65: 87–108. https://doi.org/10.3322/caac.21262 PMID: 25651787
2. Glade, M. J (1999) Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research /World Cancer Research Fund, American Institute for Cancer Research, 1997. Nutrition15: 523–526.
3. Nguyen DX, Bos PD, Massagué J (2009) Metastasis: from dissemination to organ-specific colonization. Nature Reviews Cancer 9: 274–284. https://doi.org/10.1038/nrc2622 PMID: 19308067
4. Toh Y, Nicolson GL (2009) The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis 26: 215–227. https://doi.org/10.1007/s10585-008-9233-8 PMID: 19116762
5. Toh Y, Pencil SD, Nicolson GL (1995) Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines. Gene 159: 97–104 PMID: 7607577
6. Toh Y, Kuwano H, Mori M, Nicolson GL, Sugimachi K (1999) Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. British Journal of Cancer 79: 1723–1726. https://doi.org/10.1038/sj.bjc.6690274 PMID: 10206263
7. Song L, Wang Z, Liu X (2013) MTA1: A Prognosis Indicator of Postoperative Patients with Esophageal Carcinoma. Thorac Cardiovasc Surg 61: 479–485 https://doi.org/10.1055/s-0032-1304545 PMID: 22547301
8. Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysis. Eur J Epidemiol 25: 603–605. https://doi.org/10.1007/s10654-010-9491-z PMID: 20652370

9. Toh Y, Ohta T, Endo K, Adachi E, Kusumoto H, Haraguchi M, et al (2004) Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer 110: 362–367. https://doi.org/10.1002/ijc.20514 PMID: 15095300

10. Yang H, Xu L, Qian H, Niu X, Zhao D, Zhao Z, et al (2016) Correlation between insulin-like growth factor binding protein 3 and metastasis-associated gene 1 protein in esophageal squamous cell carcinoma. Mol Med Rep 13: 4143–4150. https://doi.org/10.3892/mmr.2016.5046 PMID: 27035126

11. Li SH, Tian H, Yue WM, Li L, Gao C, Li WJ, et al (2012) Metastasis-associated Protein 1 Nuclear Expression is Closely Associated with Tumor Progression and Angiogenesis in Patients with Esophageal Squamous Cell Cancer. World J Surg 36: 623–631. https://doi.org/10.1007/s00268-011-1421-z PMID: 22270988

12. Li SH, Wang Z, Liu XY (2009) Metastasis-Associated Protein 1 (MTA1) Overexpression is Closely Associated with Shorter Disease-Free Interval After Complete Resection of Histologically Node-Negative Esophageal Cancer. World J Surg 33: 1876–1881. https://doi.org/10.1007/s00268-009-0119-y PMID: 19575142

13. Deng X, Du L, Wang C, Yang Y, Li J, Liu H, et al (2013) Close Association of Metastasis-Associated Protein 1 Overexpression with Increased Angiogenesis and Poor Survival in Patients with Histologically Node-Negative Gastric Cancer. World J Surg 37: 792–798. https://doi.org/10.1007/s00268-012-1898-0 PMID: 23283219

14. Yao Y, Feng S, Xiao M, Li Y, Yang L, Gong J (2015) MTA1 promotes proliferation and invasion in human gastric cancer cells. Onco Targets Ther 8: 1785–1794. https://doi.org/10.2147/OTT.S85383 PMID: 26229486

15. Meng QB, Kang WM, Yu JC, Liu YQ, Ma ZQ, Zhou L, et al (2015) Overexpression of Eukaryotic Translation Initiation Factor 5A2 (EIF5A2) Correlates with Cell Aggressiveness and Poor Survival in Gastric Cancer. PLoS One 10: e0119229. https://doi.org/10.1371/journal.pone.0119229 PMID: 25793713

16. Higashijima J, Kunta N, Miyatani T, Yoshikawa K, Morimoto S, Nishio M, et al (2011) Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncol Rep 26: 343–348. https://doi.org/10.3892/or.2011.1312 PMID: 21617866

17. Du B, Yang ZY, Zhong XY, Fang M, Yan YR, Qi GL, et al (2011) Metastasis-associated protein 1 induces VEGF-C and facilitates lymphangiogenesis in colorectal cancer. World J Gastroenterol 17: 1219–1226. https://doi.org/10.3748/wjg.v17.i9.1219 PMID: 21449429

18. Jin YJ, Chung YH, Kim JA, Park WH, Lee D, Seo DD, et al (2012) Factors Predisposing Metastatic Tumor Antigen 1 Overexpression in Hepatitis B Virus Associated Hepatocellular Carcinoma. Dig Dis Sci 57: 2917–2923. https://doi.org/10.1007/s10620-012-2286-z PMID: 22777614

19. Ryu SH, Chung YH, Lee H, Kim JA, Shin HD, Min HJ, et al (2008) Metastatic Tumor Antigen 1 Is Closely Associated with Frequent Postoperative Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma. Hepatology 47: 929–936. https://doi.org/10.1002/hep.22124 PMID: 18306220

20. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, et al (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinomas: correlation with poor prognosis with possible regulation. Pancreas 36: e1–9.
27. Ning Z, Gan J, Chen C, Zhang D, Zhang H (2014) Molecular functions and significance of the MTA family in hormone-independent cancer. Cancer. Metastasis Rev 33: 901–919. https://doi.org/10.1007/s10555-014-9517-1 PMID: 25341508

28. Jang KS, Paik SS, Chung H, Oh YH, Kong G (2006) MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci 97: 374–379. https://doi.org/10.1111/j.1349-7006.2006.00186.x PMID: 16630134

29. Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K, Moustafa A (2003) Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis 20: 19–24. PMID: 12650603

30. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, et al (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3: 30–37. https://doi.org/10.1038/35050532 PMID: 11146623

31. Toh Y, Kuninaka S, Endo K, Oshiro T, Ikeda Y, Nakashima H (2000) Molecular analysis of a candidate metastasis-associated gene, MTA1: possible interaction with histone deacetylase 1. J Exp Clin Cancer Res 19: 105–111. PMID: 10840944

32. Roy S, Packman K, Jeffrey R, Tenniswood M (2005) Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12: 482–491. https://doi.org/10.1038/sj.cdd.4401581 PMID: 15746940

33. Mahoney MG, Simpson A, Jost M, Noé M, Kari C, Pepe D, et al (2002) Metastasis-associated protein (MTA1) enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene 21: 2161–2170. https://doi.org/10.1038/sj.onc.1205277 PMID: 11948399